Establishment Labs Holdings Inc

Establishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Establishment Labs posts strong revenue growth and sets ambitious targets

Establishment Labs reported strong revenue growth in Q4 2022 and outlined ambitious revenue guidance for 2023, supported by strategic product launches and market expansion initiatives.
While facing challenges in managing expenses and optimizing margins, the company's focus on growth opportunities and market transformation positions it for long-term success and achieving its revenue targets.
With a solid cash position, investments in new facilities, and a clear roadmap for future growth, Establishment Labs demonstrates resilience and strategic foresight in navigating the competitive landscape.

Establishment Labs (ESTA) reports robust Q1 revenue growth and global expansion

Establishment Labs Holdings Inc (ESTA) delivered strong revenue growth and strategic advancements in Q1 2023, positioning the company for future success.
While facing challenges in managing expenses and entering new markets, the company's focus on innovation and global expansion presents promising opportunities.
With a solid financial foundation and a clear growth strategy, ESTA is poised to capitalize on market demand and drive sustainable growth in the coming quarters.

Establishment Labs Holdings Inc reports strong Q2 growth and eyes expansion in China and Europe

Establishment Labs Holdings Inc's Q2 2023 performance showcased revenue growth and strategic advancements, despite challenges in profitability margins.
The company's focus on expanding into new markets, launching innovative products, and strengthening partnerships presents promising growth opportunities.
Maintaining revenue guidance, preparing for new launches, and addressing operational challenges position the company for a strong finish to 2023.

Establishment Labs maintains revenue amid global slowdown, eyes future growth

Establishment Labs faces challenges from a global slowdown in aesthetics procedures but sees opportunities in new markets and innovative products.
The company's focus on cost control and cash preservation aligns with expectations of positive EBITDA and cash flow in the future.
Key strengths include FDA clearances, positive study outcomes, and confidence in growth prospects beyond 2023.

Establishment Labs (ESTA) reports robust Q4 revenue and eyes global expansion

Establishment Labs Holdings Inc (ESTA) demonstrated strong revenue growth and cost management in Q4 2023.
The company faces challenges in gross profit and cash utilization but is poised for improved margins and profitability in 2024 and beyond.
Opportunities lie in global expansion, market penetration with innovative products, and a focus on achieving positive cash flow in the near future.

Establishment Labs reports strong Q1 revenue and eyes global growth

Establishment Labs Holdings Inc showed strong Q1 performance with revenue of $37.2 million.
The company aims to achieve positive adjusted EBITDA by end of 2024 and positive cash flow by end of 2025.
Progress in FDA approvals, market diversification, and strategic expansion plans are key strengths.
Challenges include addressing net losses, achieving positive EBITDA, and upcoming FDA inspection.

Establishment Labs Holdings Inc reports strong Q2 performance and eyes U.S. and China growth

Establishment Labs Holdings Inc demonstrated strong revenue growth and progress towards profitability in Q2 2024.
While facing challenges in Latin America, the company is capitalizing on opportunities in the U.S. and China markets.
With a focus on new product launches and improving gross margins, the company is poised for future growth and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q1 2023 Results Conference Call May 8, 2023 4:30 PM ET Company Participants Raj Denhoy - Chief Financial Officer Juan José Chacón-Quirós - Chief Executive Officer Conference Call Participants Anthony Petrone - Mizuho Group Joshua Jennings - TD Cowen Neil Chatergy - B. Riley Securities Marie Thibault - BTIG Matt Taylor - Jefferies Operator Good afternoon.

Establishment Labs Holdings Inc. (ESTA) Q1 2023 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2023. First Quarter Highlights and Outlook First quarter worldwide revenue of $46.5 million increased 21.0% year-over-year and was a new quarterly record; excluding the impact of foreign currency changes, reven.

Establishment Labs Reports Record First Quarter 2023 Financial Results

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the closing of its previously announced public offering of 1,265,000 common shares at $71.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 165,000 additional common shares. The gross proceeds to t.

Establishment Labs Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2023 after the market closes on Monday, May 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada).

Establishment Labs to Announce First Quarter 2023 Financial Results on May 8

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the pricing of its public offering of 1,100,000 common shares at a price of $71.50 per share. The gross proceeds to Establishment Labs, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be ap.

Establishment Labs Announces Pricing of Public Offering of Common Shares

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has commenced a public offering of its common shares, to be sold by the Company in a registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares to be sold.

Establishment Labs Announces Proposed Public Offering of Common Shares

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the first quarter of 2023. In the three months ended March 31, 2023, the Company's revenue is expected to be approximately $46.5 million, as compared to $38.5 million for the three months ended March 31, 20.

Establishment Labs Announces Preliminary Unaudited Results for First Quarter 2023

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today noted the presentation of a study update on the Motiva US IDE Study. The update included three-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr.

Establishment Labs Notes Presentation of 3-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2023

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the launch of Mia Femtech™ (“Mia®”) in Japan, marking the beginning of a new era in breast aesthetics. “In 2013, we recognized that traditional breast augmentation was not meeting the needs of most women in Japan. Now, a decade later, we are providing a solution.

Establishment Labs Begins a New Era in Breast Aesthetics with Launch of Mia Femtech in Japan

Establishment Labs Holdings Inc. (ESTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Establishment Labs Holdings Inc. (ESTA) Stock Jumps 6.1%: Will It Continue to Soar?

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2023, which is being held April 19-23 in Miami, Florida. At the meeting, Dr.

Establishment Labs Announces Participation in The Aesthetic Meeting 2023

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed three million Motiva® devices in market. “Since its founding, Establishment Labs has been guided by one core principle: putting women at the center of everything we do,” said Juan José Chacón-Quirós, Establishment Labs CEO and Founder.

Establishment Labs Surpasses Three Million Motiva Devices

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into agreements with four partners in Europe and a second partner chain in Japan for Mia Femtech™ (“Mia®”).

Establishment Labs Announces First Mia Femtech™ Partners in Europe and Second Partner Chain in Japan

NEW YORK--(BUSINESS WIRE)---- $ESTA #ESTA--WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Establishment Labs Holdings Inc. (NASDAQ: ESTA) resulting from allegations that the Company may have issued materially misleading business information to the investing public.

ESTA INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Establishment Labs Holdings Inc. Investors to Inquire About Securities Class Action Investigation – ESTA

NEW YORK , March 1, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Establishment Labs Holdings Inc. (NASDAQ: ESTA) resulting from allegations that the Company may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Establishment Labs securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Establishment Labs Holdings Inc. Investors with Losses to Inquire About Securities Class Action Investigation - ESTA

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 9:50 am Eastern Time.

Establishment Labs to Present at the Cowen 43rd Annual Health Care Conference

Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Raj Denhoy - Chief Financial Officer Juan Jose Chacon-Quiros - Chief Executive Officer Conference Call Participants Zach Weiner - Jefferies Josh Jennings - Cowen George Sellers - Stephens Anthony Petrone - Mizuho Group Neil Chatterji - B. Riley Securities Sam Eiber - BTIG Operator Greetings, and welcome to the Establishment Labs Fourth Quarter 2022 Financial Results Conference Call.

Establishment Labs Holdings Inc. (ESTA) Q4 2022 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States.

Establishment Labs Submits Module Four to U.S. FDA for Premarket Approval of Motiva and Reports Record Fourth Quarter and Full Year 2022 Financial Results

The average of price targets set by Wall Street analysts indicates a potential upside of 43% in Establishment Labs Holdings Inc. (ESTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Establishment Labs Holdings Inc. (ESTA) Have the Potential to Rally 43.03% as Wall Street Analysts Expect?

NEW YORK , Feb. 18, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Establishment Labs Holdings Inc. (NASDAQ: ESTA) resulting from allegations that the Company may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Establishment Labs securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Establishment Labs Holdings Inc. Investors to Inquire About Securities Class Action Investigation - ESTA

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2022, after the market closes on Monday, February 27, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs to Announce Fourth Quarter 2022 Financial Results on February 27

The mean of analysts' price targets for Establishment Labs Holdings Inc. (ESTA) points to a 42.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 42.71% Upside in Establishment Labs Holdings Inc. (ESTA): Here's What You Should Know

SANTA BARBARA, Calif.--( BUSINESS WIRE )--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited revenue for the three months and fiscal year ended December 31, 2022.

Establishment Labs Announces Preliminary Unaudited Revenue for Fourth Quarter and Fiscal Year 2022

SANTA BARBARA, Calif.--( BUSINESS WIRE )--Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into an agreement with Seishin Plastic and Aesthetic Surgery Clinic in Japan for Mia Femtech™ (“Mia®”).

Establishment Labs Announces Seishin Plastic and Aesthetic Surgery Clinic in Japan as First Clinic Partner in Global Launch of Mia Femtech™

SANTA BARBARA, Calif.--( BUSINESS WIRE )--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 7:30 a.m. Pacific Time.

News for Establishment Labs Holdings Inc Stock (ESTA)